|
04 Jul 2025 |
SIS
|
Consensus Share Price Target
|
371.30 |
412.25 |
- |
11.03 |
buy
|
|
|
|
|
05 May 2025
|
SIS
|
Keynote Capitals Ltd
|
371.30
|
361.00
|
325.35
(14.12%)
|
Target met |
Buy
|
|
|
Quarterly Update Q4FY25
|
|
01 May 2025
|
SIS
|
Motilal Oswal
|
371.30
|
400.00
|
337.50
(10.01%)
|
7.73 |
Buy
|
|
|
SIS (SECIS)’s 4QFY25 revenue was up 9.3% YoY/1.9% QoQ at INR34.27b, largely in line with our estimate of INR34.6b. Revenue growth was aided by 12.9% YoY growth in Facility management, whereas India Security/International security posted 9.6%/7.7% growth YoY.
|
|
30 Jan 2025
|
SIS
|
Keynote Capitals Ltd
|
371.30
|
414.00
|
330.80
(12.24%)
|
11.50 |
Buy
|
|
|
Quarterly Update Q3FY25
|
|
31 Oct 2024
|
SIS
|
Keynote Capitals Ltd
|
371.30
|
483.00
|
402.00
(-7.64%)
|
30.08 |
Buy
|
|
|
Quarterly Update Q2FY25
|
|
30 Oct 2024
|
SIS
|
Axis Direct
|
371.30
|
540.00
|
400.85
(-7.37%)
|
45.43 |
Buy
|
|
|
Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock
|
|
29 Oct 2024
|
SIS
|
Motilal Oswal
|
371.30
|
480.00
|
386.05
(-3.82%)
|
29.28 |
Buy
|
|
|
SIS (SECIS)’s 2QFY25 revenue was up 6.3% YoY/4.4% QoQ at INR32.68b, largely in line with our estimate of INR34.51b.
|
|
29 Jul 2024
|
SIS
|
Keynote Capitals Ltd
|
371.30
|
585.00
|
421.25
(-11.86%)
|
57.55 |
Buy
|
|
|
Quarterly Update Q1FY25
|
|
26 Jul 2024
|
SIS
|
Axis Direct
|
371.30
|
540.00
|
419.75
(-11.54%)
|
45.43 |
Buy
|
|
|
We maintain our BUY recommendation on the stock.
|
|
06 May 2024
|
SIS
|
Keynote Capitals Ltd
|
371.30
|
441.00
|
440.50
(-15.71%)
|
Target met |
Buy
|
|
|
Quarterly Update Q4FY24
|
|
03 May 2024
|
SIS
|
Axis Direct
|
371.30
|
540.00
|
455.15
(-18.42%)
|
|
Buy
|
|
|
Recommendation: Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock.
|
|
01 Feb 2024
|
SIS
|
Axis Direct
|
371.30
|
540.00
|
488.50
(-23.99%)
|
|
Buy
|
|
|
Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock.
|
|
01 Feb 2024
|
SIS
|
Keynote Capitals Ltd
|
371.30
|
741.00
|
488.50
(-23.99%)
|
|
Buy
|
|
|
Quarterly Update Q3FY24
|
|
01 Nov 2023
|
SIS
|
Keynote Capitals Ltd
|
371.30
|
794.00
|
429.40
(-13.53%)
|
|
Buy
|
|
|
Quarterly Update Q2FY24
|
|
01 Nov 2023
|
SIS
|
Axis Direct
|
371.30
|
475.00
|
429.40
(-13.53%)
|
Target met |
Buy
|
|
|
Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock.
|
|
21 Sep 2023
|
SIS
|
Keynote Capitals Ltd
|
371.30
|
837.00
|
426.10
(-12.86%)
|
|
Buy
|
|
|
Initiating Coverage Report
|
|
28 Jul 2023
|
SIS
|
Axis Direct
|
371.30
|
475.00
|
434.65
(-14.57%)
|
Target met |
Buy
|
|
|
Recommendation: Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock.
|
|
05 May 2023
|
SIS
|
Axis Direct
|
371.30
|
425.00
|
383.35
(-3.14%)
|
Target met |
Buy
|
|
|
Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock.
|
|
06 Feb 2023
|
SIS
|
Axis Direct
|
371.30
|
425.00
|
345.95
(7.33%)
|
Target met |
Buy
|
|
|
Recommendation: Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock.
|
|
04 Nov 2022
|
SIS
|
Axis Direct
|
371.30
|
475.00
|
411.35
(-9.74%)
|
Target met |
Buy
|
|
|
We recommend a BUY rating on the stock and assign an 18x P/E multiple to its FY24E earnings of Rs 28.4/share which gives a TP of Rs 475/share, implying an upside of 15% from the CMP.
|
|
06 May 2022
|
SIS
|
Axis Direct
|
371.30
|
590.00
|
486.40
(-23.66%)
|
|
Buy
|
|
|
We recommend a BUY rating on the stock and assign a 21x P/E multiple to its FY24E earnings of Rs 28.4/share which gives a TP of Rs 590/share, implying an upside of 13% from the CMP.
|